Trajectory analysis suggested a CD16+ CD8+ T cell population (previously termed CD8+ NK TEMRA cells) as a final state of CD8+ terminal effector differentiation that seemed to differ in phenotypic characteristics between mild and severe COVID-19. This evidence concerns the gene CD8A and COVID-19.